ESR1 and breast cancer: Indeed, palbociclib has demonstrated statistically and clinically significant improvements in progression-free survival among patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) advanced breast cancer [11,12,13,14].